Major US pharmaceutical companies are planning to increase list prices on at least 350 medicines in 2026, with typical hikes around 4 percent. This comes despite President Trump's efforts to lower prescription drug costs and align them with prices in other wealthy nations. While some manufacturers will cut prices on certain drugs, notably after Medicare negotiations, others are proceeding with increases on a wide range of products, including vaccines and cancer therapies. Experts suggest these moves highlight ongoing challenges in addressing broader drivers of high drug costs.